La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Hepion Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Hepion Pharmaceuticals..

Hepion Pharmaceuticals (NASDAQ:HEPA) Azioni, Catena delle Opzioni

Hepion Pharmaceuticals

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals Inc

Macro Economic Events

News

Econ #s

Economics

USA Gasoline Inventories 0.412M Barrel Build Vs 1.650M Barrel Draw Est.; 2.707M Barrel Draw Prior

EIA Weekly Distillates Stocks 2.947M Barrel Build Vs 1.500M Barrel Draw Est.; 0.977M Barrel Draw Prior

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 15.97% on an annualized basis producing an average annual return of 29.67%. Currently, Iron Mountain has a market capitalization of $37.08 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $364.41 today based on a price of $126.40 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907021_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Iron Mountain 5 Years Ago Would Be Worth This Much Today

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.16% on an annualized basis producing an average annual return of 19.86%. Currently, Williams Companies has a market capitalization of $66.91 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,469.20 today based on a price of $53.05 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $78 to $75.

Price Target

Analyst Ratings

BRKR

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75

Macro Notification

General

USA Crude Oil Inventories 2.149M Barrel Build Vs 0.300M Barrel Build Est.; 0.515M Barrel Draw Prior

Susquehanna analyst Mehdi Hosseini maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $50 to $48.

Susquehanna Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $48

RBC Capital analyst Jimmy Shan maintains Colliers Intl Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#TSX">CIGI</a>) with a Outperform and lowers the price target from C$174 to C$170.

CIGI

TSX:CIGI

RBC Capital Maintains Outperform on Colliers Intl Gr, Lowers Price Target to C$170

Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and raises the price target from $78 to $88.

GMED

Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $88

RBC Capital analyst Maurice Choy reiterates Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Sector Perform and maintains C$65 price target.

Reiteration

TSX:FTS

RBC Capital Reiterates Sector Perform on Fortis, Maintains C$65 Price Target

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $160 to $171.

MASI

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $171

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 1,200 points on Wednesday.
The Dow traded up 2.90% to 43,445.79 while the NASDAQ rose 2.03% to 18,813.03. The S&amp;P 500 also rose, gaining, 1.77% to 5,884.97.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41774936/how-to-earn-500-a-month-from-qualcomm-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 4.4% on Tuesday.
In trading on Tuesday, real estate shares fell by 1.8%.
Top Headline
Former President Donald Trump declared victory in the 2024 presidential election after winning the key battleground states.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares shot up 171% to $0.3718.</li>
<li>Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) got a boost, surging 110% to $8.82 after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.</li>
<li>Trilogy Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#NYSE">TMQ</a>) shares were also up, gaining 73% to $0.9835.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares dropped 42% to $4.12.</li>
<li>Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) were down 40% to $7.94 after the company announced the pricing of $9.15 million private placement.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) was down, falling 35% to $19.14 after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $71.50 while gold traded down 2.8% at $2,672.20.
Silver traded down 4.8% to $31.215 on Wednesday, while copper fell 4.6% to $4.2690.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX dipped 1.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 3.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 2.61%, Hong Kong's Hang Seng Index falling 2.23%, China's Shanghai Composite Index falling 0.09% and India's BSE Sensex gaining 1.13%.
Economics
U.S. mortgage applications fell by 10.8% from the previous week in the week ended Nov. 1.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41773566/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

FOXO

NOVA

PACS

SONN

ZCAR

Dow Jumps Over 1,200 Points; Donald Trump Wins White House

Wells Fargo analyst Stephen Baxter maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and raises the price target from $275 to $285.

Wells Fargo Maintains Overweight on Universal Health Servs, Raises Price Target to $285

RBC Capital analyst Greg Pardy maintains Imperial Oil (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#TSX">IMO</a>) with a Sector Perform and raises the price target from C$99 to C$101.

TSX:IMO

RBC Capital Maintains Sector Perform on Imperial Oil, Raises Price Target to C$101

RBC Capital analyst Jimmy Shan maintains InterRent REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IIP#TSX">IIP</a>) with a Outperform and lowers the price target from C$16.5 to C$15.

TSX:IIP

TSX:IIP/UN

RBC Capital Maintains Outperform on InterRent REIT, Lowers Price Target to C$15

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)&nbsp;reported third-quarter sales of $95.43 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $92.75 billion</a>.&nbsp;
Total revenues increased 6.3%, primarily driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769047/cvs-health-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">Health Services segment</a>.
Adjusted EPS of $1.09 (inline with preliminary guidance of $1.05-$1.10) decreased from $2.21 in the prior year, missing the consensus of $1.53. The fall was primarily due to a decline in the Health Care Benefits segment&#8217;s operating results, which reflects continued utilization pressure and premium deficiency reserves of approximately $1.1 billion, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual <a target="_blank" href="https://www.benzinga.com/news/24/11/41719665/cvs-health-q3-earnings-preview-can-the-company-overcome-recent-challenges" rel="noreferrer noopener">exchange product lines</a>.
Adjusted operating income decreased 77.5% to $2.55 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41429974/cigna-and-humana-revive-early-merger-talks-after-year-long-pause-as-medicare-cost-pressure-looms" rel="noreferrer noopener">Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms</a>
During the third quarter of 2024, CVS Health <a target="_blank" href="https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2024/Q3-2024-Earnings-Release.pdf" rel="noreferrer noopener">finalized</a> its restructuring plan and recorded restructuring charges of approximately $1.2 billion, including store impairment charges for additional retail pharmacy stores it plans to close in 2025.
Revenues in the Health Care Benefits segment increased 25.5% to $32.99 billion. The Medical benefit ratio increased to 95.2% from 85.7% a year ago. Medical membership reached 27.1 million.
Health Services segment revenues decreased 5.9% to $44.13 billion. Pharmacy claims processed decreased 16.5%.
Concurrently, CVS&nbsp;Health announced&nbsp;that Prem&nbsp;Shah will be Group President and responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna. Both appointments are effective today.
Pharmacy &amp; Consumer Wellness segment revenues increased 12.3% to $32.42 billion, primarily driven by increased prescription volume, including increased contributions from vaccinations and pharmacy drug mix.
In October, CVS Health appointed David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company&#8217;s&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41398693/cvs-health-appoints-david-joyner-president-and-chief-executive-officer" rel="noreferrer noopener">ongoing financial struggles</a>.
The company also withdrew the 2024 guidance provided in the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">second-quarter earnings release</a>.
Price Action:&nbsp;CVS stock is up 11.30% at $61.60&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41754167/why-is-astrazeneca-stock-sinking-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is AstraZeneca Stock Sinking On Tuesday?</a></li>
</ul>
Image via Shutterstock

Large Cap

Guidance

Health Care

Movers

CVS Health Stock Jumps After Mixed Q3 Earnings, Takes $1.2 Billion Restructuring Charges Hit

RBC Capital analyst Irene Nattel maintains Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) with a Outperform and raises the price target from C$34 to C$35.

TSX:PET

RBC Capital Maintains Outperform on Pet Valu Hldgs, Raises Price Target to C$35

WIIM

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

XPEV

Shares of US-listed Chinese stocks are trading higher after Donald Trump was elected president of the United States, which could raise concerns over potential tariffs and US-China tensions.

Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $195 to $205.

Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $205

Warren Buffett, one of the world&#8217;s most successful investors, has shared plenty of advice over his long career. But one <a href="https://www.benzinga.com/news/23/07/33245523/warren-buffetts-no-1-investing-rule-dont-lose-money-practical-advice-for-a-billionaire-but-can-regul">piece of advice</a> stands out as his top rule: &#8220;The first rule of investment is don&#8217;t lose money.&#8221; And if you ask about the second rule? &#8220;Don&#8217;t forget the first.&#8221; According to Buffett, that&#8217;s all you need to know.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">1. Warren Buffett "Rule no.1 is don't lose and the second rule is never forget rule 1." &#x1f410; <a href="https://t.co/x0hEOgxVJ4">pic.twitter.com/x0hEOgxVJ4</a>
&mdash; Oliver &#x7C; MMMT Wealth (CPA) (@MMMTwealth) <a href="https://twitter.com/MMMTwealth/status/1850983304167571542?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
It might sound simple — even a bit obvious. After all, who wants to lose money? But Buffett's point is more profound than it might first appear. <a href="https://www.benzinga.com/news/24/09/41091380/warren-buffet-tells-investors-to-give-up-on-me-vs-stock-approach-what-tells-you-whether-you-should-k">His investment philosophy</a> is about protecting what you already have. If you lose a big chunk of your investment, you need a huge return just to get back to where you started.&nbsp;
For example, when a stock drops by a big margin, it requires an even greater gain just to get back to its original value. It's much easier to prevent these kinds of losses in the first place than to claw your way back from them.&nbsp;
Of course, saying &#8220;don't lose money&#8221; is easier than actually following through, especially with the ups and downs of the stock market. But there are practical strategies investors can use to help follow Buffett&#8217;s rule.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
You lower the chance of suffering a significant loss on any one investment by <a href="https://www.benzinga.com/money/how-to-diversify-your-portfolio">distributing your funds over several stocks or sectors</a>. Your portfolio can still be balanced even if one or two stocks do not perform well.
Buffett is known for investing in businesses with <a href="https://www.benzinga.com/startups/24/10/41252767/warren-buffetts-timeless-advice-is-to-invest-in-stocks-that-youd-be-perfectly-happy-to-hold-if-the-m">strong fundamentals</a> that he believes will be successful for many years to come. He prefers companies with a competitive edge, solid management, and products people will continue to buy. Instead of chasing the cheapest stocks, he looks for good companies at reasonable prices.
The market can be a rollercoaster, and emotions like fear or greed often cause people to make costly mistakes. Buffett's approach is to stay calm when others are panicking and to make decisions based on logic, not emotion.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
It's worth noting that even Warren Buffett has lost money, and he has been open about what he thinks are his biggest investment mistakes. He has also stated that one of his worst missteps was purchasing Berkshire Hathaway, a textile company that was initially in decline. Nevertheless, Buffett has been successful over the long term despite these setbacks because he is focused on limiting losses and learning from his mistakes.
<h2 class="wp-block-heading">Alternative Opinions</h2>
On the other hand, some investors think that taking measured risks, even at the expense of occasional losses, is a necessary component of attaining sizable returns, even if Buffett&#8217;s advice to avoid losses is generally accepted. <a href="https://www.benzinga.com/personal-finance/24/06/39360926/diversification-thats-for-idiots-mark-cuban-slams-warren-buffetts-investment-strategy-i-think-bu">Mark Cuban, for example, once said</a>, &#8220;Diversification, that&#8217;s for idiots&#8221; and that &#8220;buy and hold is a crock of s&#x2A;&#x2A;&#x2A;.&#8221;
Plus, startups, emerging technologies, and high-growth companies often come with higher risk but also the potential for substantial gains — something that Buffett's cautious approach might miss.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

'The First Rule Of Investment Is Don't Lose,' Says Warren Buffett. The Second Rule? Don't Forget The First — 'That's All The Rules'

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the fourth quarter of 2023.<ul><li>Hepion Pharmaceuticals reported earnings per share of -$2.42. This was above the analyst estimate for EPS of -$2.63.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/hepa-stock-earnings-hepion-pharmaceuticals-for-q4-of-2023/">HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Beats EPS for Q4 2023

Hepion ends Phase 2 study for NASH drug due to cash restraints

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

SBFM, BPTH and INDO among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving on Monday after the biopharmaceutical company announced plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.



A press release from the company notes that it is winding down it Phase 2b ASCEND-NASH study. The failure of the study comes as it couldn&rsquo;t reach the planned 336 patients. Instead, it only got to 151 patients.



On top of this, Hepion Pharmaceuticals is struggling with resources as the company is exploring strategic alternatives. This didn&rsquo;t leave it with enough room to keep the trial going while waiting for more patients to enroll.



Hepion Pharmaceuticals executive chairman John Brancaccio said the following about the news.




&ldquo;We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner.&rdquo;




<h2>HEPA Stock Movement Today</h2>



With this news comes a 40.5% drop for HEPA stock on Monday morning. Investors will note that the shares were already down 36.2% year-to-date when markets closed on Friday.



This also comes with around 39,000 shares traded. The company&rsquo;s daily average trading volume is still above that at 75,000 shares.



Investors will find even more of the most recent stock market stories ready to go below!



We are offering insight into the top stock market news for Monday! That includes everything happening with shares of Vaxxinity&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock, OLB Group&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock and Moolec Science&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock today. You can find out more on these matters at the following links!



<h2>More Stock Market News for Monday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-olb-group-olb-stock-up-27-today/">Why Is OLB Group (OLB) Stock Up 27% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-moolec-science-mlec-stock-up-121-today/">Why Is Moolec Science (MLEC) Stock Up 121% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nike (NYSE:<a href="https://investorplace.com/stock-quotes/nke-stock-quote/">NKE</a>) layoffs are in the news Monday after the athletic apparel company announced plans to <a href="https://www.kgw.com/article/money/business/nike-740-layoffs-world-headquarters-beaverton/283-3d676a3c-957d-4110-92bd-d5f7a9c793e9">cut jobs at its global headquarters</a>.



These Nike layoffs will result in 740 employees at the company&rsquo;s Beaverton, Oregon, headquarters losing their jobs. This comes after the company announced plans to reduce its workforce by 2% in February.



Nike is planning to handle these layoffs in two rounds. The first round will start immediately, and the second round will <a href="https://www.usatoday.com/story/money/business/2024/04/20/nike-layoffs-2024/73396096007/">start by June 28</a>. It&rsquo;s worth noting that Nike currently has about 11,000 employees at its headquarters and 83,000 total.



All of this is part of a restructuring effort that has 1,600 jobs being cut at Nike. The company estimates that these changes will save it $2 billion per year and that it will suffer a $400 million to $450 million charge connected to them.



<h2>Nike Layoffs Statement</h2>



Here&rsquo;s what the company had to say about the layoffs to KGW8:




&ldquo;Nike&rsquo;s always at our best when we&rsquo;re on the offense. The actions that we&rsquo;re taking put us in the position to right-size our organization to get after our biggest growth opportunities as interest in sport, health and wellness have never been stronger.&rdquo;




NKE stock is down slightly on Monday morning after announcing this newest round of layoffs.



Investors who are seeking out even more of the most recent stock market stories are in luck!



We have all of the hottest stock market news for Monday! Among that is what has shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Hepion Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) and Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock in the news today. You can read up on all of this news at the links below!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/tsla-stock-alert-tesla-plunges-on-another-round-of-ev-price-cuts/">TSLA Stock Alert: Tesla Plunges on Another Round of EV Price Cuts</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-hepion-pharmaceuticals-hepa-stock-down-41-today/">Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-vaxxinity-vaxx-stock-down-58-today/">Why Is Vaxxinity (VAXX) Stock Down 58% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/nike-layoffs-2024-what-to-know-about-the-latest-nike-job-cuts/">Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts

MRIN, WISA and SMFL among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the first quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -56 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/hepa-stock-earnings-hepion-pharmaceuticals-for-q1-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024

An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...

Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) just reported results for the second quarter of 2024.<ul><li>Hepion Pharmaceuticals reported earnings per share of -68 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/hepa-stock-earnings-hepion-pharmaceuticals-for-q2-of-2024/">HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q2 2024

AGBA

AILE

AKRO

ARWR

ASCLF

BPTH

BPTS

BSGM

CAPT

CHRO

CSLR

DRMA

EDBL

ETNB

EZFL

GALT

GILD

GLMD

GRTX

HEPA

HGAS

HUBC

INDO

INVO

IONS

MDGL

MDIA

MLEC

MNDR

MRIN

MTTR

NKGN

NVFY

PAAS

PALI

PROK

PRTG

RWOD

SBFM

SGMT

SMFL

SOAR

SPCB

TELO

TERN

TRSG

TSLA

VAXX

VKTX

VZLA

WISA

YYGH

ZCMD

Press Releases

Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease

Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit

Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes

Hepion Pharmaceuticals to Present at NASH-TAG 2024

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

Comments

Hepion Pharmaceuticals

Hepion Pharmaceuticals (HEPA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO